Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/functional-inactivation-of-cd4-cd25high-regulatory-t-cells-using-low-ykxA9THKhU
References (29)
-
C. Kudo-Saito, J. Schlom, K. Camphausen, C. Coleman, J. Hodge (2005)
The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established TumorsClinical Cancer Research, 11
-
SA Rosenberg, BS Packard, PM Aebersold (1988)
Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanomaA preliminary report. N Engl J Med, 319
-
M. Dudley, J. Wunderlich, J. Yang, P. Hwu, D. Schwartzentruber, S. Topalian, R. Sherry, F. Marincola, S. Leitman, C. Seipp, Linda Rogers-Freezer, K. Morton, Azam Nahvi, S. Mavroukakis, D. White, S. Rosenberg (2002)
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic MelanomaJournal of Immunotherapy, 25
-
S Hori, T Nomura, S Sakaguchi (2003)
Control of regulatory T cell development by the transcription factor FOXP3Science, 299
-
D. Lenschow, T. Walunas, J. Bluestone (1996)
CD28/B7 system of T cell costimulation.Annual review of immunology, 14
-
I. Caras, A. Grigorescu, C. Stăvaru, D. Radu, I. Mogos, G. Szegli, A. Salageanu (2004)
Evidence for immune defects in breast and lung cancer patientsCancer Immunology, Immunotherapy, 53
-
V. Trouet, Jan Esper, Nicholas Graham, Andy Baker, J. Scourse, David, C. Frank (2002)
Supporting Online Material -
M. Katoh (2002)
Expression of human SOX7 in normal tissues and tumors.International journal of molecular medicine, 9 4
-
R. Angulo, D. Fulcher (1998)
Measurement of Candida-specific blastogenesis: comparison of carboxyfluorescein succinimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression.Cytometry, 34 3
-
田畑 智之 (2004)
Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers -
Y Yamaguchi, A Ohshita, Y Kawabuchi (2003)
Adoptive immunotherapy of cancer using activated autologous lymphocytes?current status and new strategiesHum Cell, 16
-
J. Dannull, Z. Su, D. Rizzieri, Benjamin Yang, Doris Coleman, Donna Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa, J. Vieweg (2005)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.The Journal of clinical investigation, 115 12
-
J. Shimizu, S. Yamazaki, S. Sakaguchi (1999)
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.Journal of immunology, 163 10
-
A. Aruga, K. Yamauchi, K. Takasaki, Takaji Furukawa, F. Hanyu (1991)
Induction of autologous tumor‐specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilizationInternational Journal of Cancer, 49
-
M. Okawaki, Y. Yamaguchi, R. Okita, M. Ôhara, M. Okada (2008)
Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusion.Hiroshima journal of medical sciences, 57 1
-
S Read, V Malmstrom, F Powrie (2000)
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4 (+) regulatory cells that control intestinal inflammationJ Exp Med, 192
-
Takeshi Takahashi, Tomoyuki Tagami, S. Yamazaki, T. Uede, J. Shimizu, N. Sakaguchi, T. Mak, S. Sakaguchi (2000)
Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4The Journal of Experimental Medicine, 192
-
S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, M. Toda (1995)
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.Journal of immunology, 155 3
-
GQ Phan, JC Yang, RM Sherry (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProc Natl Acad Sci USA., 100
-
S. Rosenberg, B. Packard, P. Aebersold, D. Solomon, S. Topalian, S. Toy, P. Simon, M. Lotze, James Yang, C. Seipp, Colleen Simpson, C. Carter, S. Bock, D. Schwartzentruber, John Wei, D. White (1988)
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.The New England journal of medicine, 319 25
-
M. Dudley, J. Wunderlich, J. Yang, R. Sherry, S. Topalian, N. Restifo, R. Royal, U. Kammula, D. White, S. Mavroukakis, L. Rogers, Gerald Gracia, S. Jones, David Mangiameli, M. Pelletier, J. Gea-Banacloche, M. Robinson, D. Berman, A. Filie, A. Abati, S. Rosenberg (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 10
-
K. Kono, Akihiro Takahashi, H. Sugai, H. Fujii, A. Choudhury, R. Kiessling, Y. Matsumoto (2002)
Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 11
-
A Aruga, K Yamauchi, K Takasaki (1991)
Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancerInt J Cancer, 49
-
G. Phan, J. Yang, R. Sherry, P. Hwu, S. Topalian, D. Schwartzentruber, N. Restifo, Leah Haworth, C. Seipp, Linda Freezer, K. Morton, S. Mavroukakis, P. Duray, S. Steinberg, J. Allison, T. Davis, S. Rosenberg (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProceedings of the National Academy of Sciences of the United States of America, 100
-
D. Boczkowski, S. Nair, D. Snyder, E. Gilboa (1996)
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivoThe Journal of Experimental Medicine, 184
-
A. Rowshani, A. Uss, S. Yong, R. Lier, I. Berge (2004)
Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitroEuropean Journal of Immunology, 34
-
P. Waterhouse, J. Penninger, E. Timms, A. Wakeham, A. Shahinian, Kelvin Lee, C. Thompson, H. Griesser, T. Mak (1995)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 270
-
S. Rosenberg, M. Lotze, L. Muul, S. Leitman, A. Chang, S. Ettinghausen, Y. Matory, J. Skibber, E. Shiloni, J. Vetto, C. Seipp, Colleen Simpson, C. Reichert (1985)
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.The New England journal of medicine, 313 23
-
S. Read, V. Malmström, F. Powrie
Brief Definitive Report Cytotoxic T Lymphocyte–associated Antigen 4 Plays an Essential Role in the Function of Cd25 Ϩ Cd4 Ϩ Regulatory Cells That Control Intestinal Inflammation
- Publisher
- Springer Journals
- Copyright
- Copyright © 2008 by Springer-Verlag
- Subject
- Medicine & Public Health; Biomedicine general; Oncology
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-008-0095-4
- Publisher site
- See Article on Publisher Site
Abstract
Functional modulation of regulatory T cells (T-regs) is one possible approach to cancer immunotherapy. In this study, we investigated whether low-dose basiliximab, a chimeric anti-CD25 monoclonal antibody, could suppress the T-regs function not by depletion but by inactivation, and increase immune responses. Peripheral blood mononuclear cells from healthy donors and patients with malignancy were collected. We tried T-regs inactivation using various concentrations of basiliximab before induction of lymphokine-activated killer (LAK) cells. We measured cell proliferation, lymphocyte phenotype, intracellular T-regs maker, and Th1/2 cytokines production. Our results showed that the optimal concentration of basiliximab for specifically down-modulating only T-regs was 0.001 μg/ ml. The reduction of Th-2 cytokine secretion with concomitant APC induction without suppressing cell proliferation offers the promise of a novel adoptive immunotherapy to cancer patients.
Journal
Targeted Oncology – Springer Journals
Published: Nov 11, 2008